The GI-MAP is a stool test that uses quantitative PCR to measure the DNA of specific gut organisms and a set of intestinal health markers, reporting each as a number against the laboratory's own reference range. It is one of the more widely used gut health tests in functional medicine, and it is also one of the most over-interpreted. Understanding what it genuinely measures, where the validation is solid and where it is thin, and how a result should change a plan is the difference between a useful investment and an expensive printout. This article covers the method, the panel, the markers, the limitations, the cost question and how results drive a protocol.
Free interactive tool
Stool test readiness check
Tick what describes your situation to see whether a stool panel is likely to change what happens next, or whether cheaper steps come first.
In this article
- qPCR counts DNA sequences and behaves differently from stool culture and from 16S sequencing
- The panel splits into pathogens, commensals, opportunists, fungi, parasites and intestinal markers
- Calprotectin is well validated; zonulin as a permeability marker is not
- Optimal ranges are laboratory-derived, not outcome-validated consensus ranges
- The test is a laboratory developed test run in a CLIA-certified lab, which is not the same as FDA clearance
- It is usually a cash-pay test, and insurance coverage is uncommon
- A result is only useful if it changes a decision
What a GI-MAP actually measures
The panel is a single stool sample analyzed for a fixed list of targets. It is not a survey of your whole microbiome. It reports the specific organisms and markers the assay is built to detect, in six broad groups.
| Group | What is reported | Clinical use | How much weight it carries |
|---|---|---|---|
| Pathogens | Recognized bacterial pathogens such as C. difficile toxin genes, Salmonella, Shigella, Campylobacter, plus viral targets | Identifying a genuine infectious cause | High, when positive and clinically consistent |
| Parasites and protozoa | Giardia, Cryptosporidium, Entamoeba histolytica, plus organisms of uncertain significance such as Blastocystis and Dientamoeba | Investigating post-travel or post-infectious symptoms | Mixed; pathogenicity of several organisms is genuinely contested |
| Commensal bacteria | Quantities of normal residents including Akkermansia muciniphila, Faecalibacterium prausnitzii, Bacteroides and Bifidobacterium | Describing the state of the resident community | Low to moderate; the ranges are descriptive, not diagnostic |
| Opportunistic bacteria | Organisms that are normally present in small numbers and can overgrow, including Pseudomonas, Klebsiella, Staphylococcus and Streptococcus species | Flagging dysbiotic patterns | Moderate, and only in the context of symptoms |
| Fungi and yeast | Candida species, Geotrichum, Microsporidia | Assessing suspected fungal overgrowth | Candida is common in healthy stool, so results are hard to interpret |
| Intestinal health markers | Calprotectin, secretory IgA, pancreatic elastase, steatocrit, beta-glucuronidase, zonulin | Inflammation, immunity, digestion and detoxification signals | Varies enormously by marker, as below |
Two structural points follow from that list. First, the test answers only the questions it was designed to ask, so an organism not on the panel is not reported as absent, it is simply not looked for. Second, quantities of commensals are the section most likely to be over-read, because they are reported with the same numerical confidence as the pathogen results while resting on far weaker interpretive ground.
qPCR versus culture versus sequencing
The method matters more than most patients are told, because each approach answers a different question.
| Method | What it detects | Strengths | Limitations |
|---|---|---|---|
| Quantitative PCR, used by GI-MAP | DNA sequences specific to targeted organisms, quantified against standards | Sensitive, reproducible, detects organisms that will not grow in culture, unaffected by whether the organism arrived alive | Only finds what it targets; detects DNA from dead organisms; abundance is relative to the sample, not an absolute census |
| Stool culture | Live organisms able to grow on selective media | Long-established, allows antibiotic sensitivity testing on the isolate | Misses the large majority of gut anaerobes, which do not culture; slow; heavily dependent on handling |
| 16S rRNA sequencing | A region of bacterial DNA present across species, giving a community profile | Broad view of community composition and diversity without preselecting targets | Usually genus-level resolution; results vary with method and pipeline; consumer reports can read more into results than they support |
| Shotgun metagenomics | All DNA in the sample, including functional genes | Highest resolution, species and strain level, functional potential | Expensive; interpretation is still largely a research activity |
The practical implication is that a qPCR panel is well suited to answering "is this specific organism present, and roughly how much", and poorly suited to answering "how healthy is my microbiome overall". Any test that offers a single gut health score is compressing a research-grade question into one number.
The intestinal markers, graded by evidence
The markers section is where a stool panel earns most of its clinical value, and the individual results sit at very different evidence levels. Treating them as one block is the commonest interpretive error.
Marker by marker
| Marker | What it reflects | Evidence status |
|---|---|---|
| Fecal calprotectin | Neutrophil protein released during intestinal inflammation | Strong. Used in mainstream gastroenterology to distinguish inflammatory bowel disease from IBS and to monitor disease activity. A meaningfully raised value warrants gastroenterology referral, not a supplement protocol |
| Pancreatic elastase-1 | Exocrine pancreatic enzyme output | Strong. A validated screen for exocrine pancreatic insufficiency, with low values requiring proper follow-up |
| Steatocrit | Fat content of stool | Moderate. A crude but useful signal of fat malabsorption |
| Secretory IgA | Mucosal antibody secretion | Moderate as a research measure, weak as an individual diagnostic. Values move with acute illness, stress and sampling variation |
| Beta-glucuronidase | Bacterial enzyme that can deconjugate estrogens and other compounds in the gut | Emerging. Mechanistically interesting, particularly for estrogen recirculation, but not validated as a clinical decision threshold |
| Zonulin | Marketed as a marker of intestinal permeability | Weak. Published work has shown commercial zonulin assays cross-react with other proteins, so the number should not be treated as a permeability measurement |
Short-chain fatty acids sit in a similar position to secretory IgA. They are the products of bacterial fiber fermentation and matter biologically, but a fecal measurement reflects what was not absorbed rather than what was produced, which makes a low result ambiguous. We discuss both the value and the limits of permeability testing in leaky gut signs, causes and testing.
Optimal ranges, reference ranges and regulatory status
This is the section most articles about functional testing leave out, and it is the one that determines how much weight a result deserves.
A conventional laboratory reference range is usually derived from a defined population and anchored, for well-established analytes, to clinical outcomes. The abundance ranges reported for commensal and opportunistic organisms on functional stool panels are largely laboratory-derived: they describe how a target is distributed across the samples that laboratory has run, using its own assay. That is legitimate as an internal comparison and it is not the same thing as an outcome-validated threshold. A number flagged high does not automatically mean it is causing your symptoms.
On regulatory status, the GI-MAP is a laboratory developed test performed in a CLIA-certified laboratory (Diagnostic Solutions Laboratory). CLIA certification governs how a laboratory operates and validates its assays; it is not equivalent to FDA clearance of a diagnostic claim, and the oversight of laboratory developed tests remains an active area of policy at the FDA. Individual assays on the panel have method-validation data behind them, and the quality of that data varies target by target, which is precisely why the markers above deserve different amounts of trust.
It is also worth stating what professional bodies say. The American College of Gastroenterology's IBS guideline recommends against routine stool testing for enteric pathogens in all patients with IBS. We are not aware of guidance from the American Gastroenterological Association or the American College of Gastroenterology that recommends microbiome profiling for routine diagnosis of functional gastrointestinal symptoms. A 2025 international expert consensus found there is not yet enough evidence to widely recommend routine microbiome testing in clinical practice, and said multiplex PCR panels cannot be used as a proxy for microbiome profiling. The defensible position is that a panel like this is a clinical adjunct used by a clinician who knows its limits, not a diagnostic authority.
Who benefits from a stool test, and who does not
The test earns its place when a result would change what happens next.
- Reasonable candidates. Persistent digestive symptoms that have not resolved with first-line management; symptoms that began after travel, food poisoning or a course of antibiotics; unexplained loose stool or fat malabsorption; symptoms alongside an autoimmune diagnosis; recurrent yeast or urinary symptoms with digestive features; and cases where a previous empirical treatment failed and the reason is unclear.
- Poor candidates. Mild, occasional bloating that has never been approached systematically; curiosity in the absence of symptoms; anyone whose red flags have not yet been evaluated conventionally; and anyone who has not first had celiac serology, a thyroid panel, ferritin and a blood count, which are cheaper, faster and more likely to change management.
Bloating in particular has a differential that should be worked through before a stool panel, and the branches are set out in our guide to chronic bloating and its root causes. If the pattern points at fermentation in the small intestine, a breath test answers that question better than a stool test does, as covered in SIBO symptoms and testing. A stool sample describes the colon far better than the small intestine.
Interactive tool
Stool test readiness check
Tick what describes your situation to see whether a stool panel is likely to change what happens next, or whether cheaper steps come first.
What it costs
The GI-MAP is a cash-pay test in the great majority of cases. Direct list pricing has historically sat in the low-to-mid hundreds of dollars, practitioner pricing differs from consumer pricing, and both change over time, so the only reliable figure is the current one quoted by the laboratory or the ordering clinician at the time you order. Insurance reimbursement is uncommon, and where a superbill can be submitted, coverage is unpredictable and often denied for panels classed as investigational. We cover the general picture in is functional medicine covered by insurance.
Two cost points are worth weighing. Ordering a stool panel before basic conventional labs frequently means paying for the expensive test twice, once to run it and once again after the cheap test explains the picture. And a result nobody has time to interpret properly costs the same as one that changes a plan.
How results actually drive a protocol
A well-used result narrows the options rather than generating a shopping list. The pattern, the symptoms and the history are read together, and each finding maps to a decision rather than to a supplement.
From finding to decision
| Finding | How it is read | What it typically changes |
|---|---|---|
| Raised calprotectin | Inflammation, not dysbiosis | Referral for gastroenterology assessment and consideration of inflammatory bowel disease before anything else |
| Low pancreatic elastase | Possible exocrine pancreatic insufficiency | Medical evaluation of the pancreas; digestive support is symptomatic, not an answer |
| A recognized pathogen with matching symptoms | A genuine infectious contributor | Treatment directed at that organism, with the prescribing decision made by a clinician |
| Opportunistic overgrowth with matching symptoms | A dysbiotic pattern, not an infection | Attention to the terrain: digestive capacity, motility, fiber intake, and any driver such as acid suppression |
| Low commensal diversity, low Akkermansia or Faecalibacterium | Descriptive, low weight in isolation | Dietary work on plant diversity and fermentable fiber rather than a targeted product |
| Raised beta-glucuronidase with estrogen-related symptoms | Mechanistically interesting, not diagnostic | A conversation about fiber, bowel regularity and hormone assessment rather than a treatment on its own |
| Everything within range, symptoms persist | A genuinely useful negative | Redirects the workup toward motility, visceral hypersensitivity, hormonal patterns or a non-gut cause |
That last row is the one most people underestimate. A normal panel in a symptomatic woman is not a wasted test; it moves the search somewhere more productive. In our own test-interpretation reviews, the results that change management most often are the well-validated ones, calprotectin, elastase and clear pathogen positives, while the commensal abundance columns far more often refine a dietary conversation than justify a specific intervention.
If you are considering testing, the functional medicine process page sets out how a workup is sequenced, and our digestive and gut health page describes the conditions we see most often in women across Texas.
FAQ
Is the GI-MAP better than a conventional stool test?
It is different rather than uniformly better. A conventional stool study ordered through a physician targets recognized pathogens, is validated for that purpose and is usually covered by insurance. The GI-MAP adds quantification of commensal and opportunistic organisms and a set of intestinal markers, which a standard panel does not report. For diagnosing infection, conventional testing is the appropriate route. For describing a dysbiotic pattern alongside symptoms, the extra columns can add context, provided they are weighted for what they are.
Do I need to stop supplements or antibiotics before the test?
Generally yes, and the specifics should come from the ordering clinician. Antibiotics and antifungals are usually stopped several weeks beforehand, and probiotics, digestive enzymes and binders for a shorter window, because each can alter what the assay detects. Because qPCR detects DNA rather than live organisms, recently taken probiotic strains can appear in the results, which is a common source of confusing findings.
What does it mean if Blastocystis or Candida shows up?
Less than most people assume. Blastocystis hominis is found in a substantial share of asymptomatic people and its pathogenicity is genuinely debated, so treatment is not automatic and depends on symptoms, subtype considerations and what else the picture shows. Candida is commonly detected in the stool of healthy people, so finding it does not on its own show clinically meaningful overgrowth. Both findings are interpreted in the context of symptoms rather than treated on sight.
How often should a stool test be repeated?
Only when repeating it would change a decision. Retesting is reasonable after treatment for a documented pathogen, or where a validated marker such as calprotectin was raised and needs to be followed. Repeating a panel to watch commensal abundance shift is rarely informative, because the day-to-day variation in those numbers is considerable and the ranges were never anchored to outcomes in the first place.
References
- Diagnostic Solutions Laboratory. Diagnostic Solutions Laboratory. 2026. https://www.diagnosticsolutionslab.com/tests/gi-map
- Lacy BE, et al. The American Journal of Gastroenterology. 2021. https://pubmed.ncbi.nlm.nih.gov/33315591/
- Whitcomb DC, et al. Gastroenterology. 2023. https://pubmed.ncbi.nlm.nih.gov/37737818/
- Scheffler L, et al. Frontiers in Endocrinology. 2018. https://pubmed.ncbi.nlm.nih.gov/29459849/
- Diagnostic Solutions Laboratory. GI-MAP Methodology Guide. 2026. https://www.diagnosticsolutionslab.com/assets/documents/GI-MAP-Methodology-Guide.pdf
- Centers for Medicare and Medicaid Services. Centers for Medicare and Medicaid Services. 2026. https://www.cms.gov/medicare/quality/clinical-laboratory-improvement-amendments
- U.S. Food and Drug Administration. U.S. Food and Drug Administration. 2025. https://www.fda.gov/medical-devices/in-vitro-diagnostics/laboratory-developed-tests
- Lacy BE, et al. Am J Gastroenterol. 2021. https://webfiles.gi.org/links/PCC/ACG_Clinical_Guideline__Management_of_Irritable.11.pdf
- Porcari S, et al. Lancet Gastroenterol Hepatol. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12343204/
- Andersen LO, et al. Journal of Clinical Microbiology. 2016. https://pubmed.ncbi.nlm.nih.gov/26677249/
- Nash AK, et al. Microbiome. 2017. https://pubmed.ncbi.nlm.nih.gov/29178920/
About the author
Anna Evans MSN, APRN, FNP-C
Founder, Interlinked Wellness
Anna Evans, MSN, APRN, FNP-C is a board-certified Family Nurse Practitioner licensed in Texas. She founded Interlinked Wellness, a virtual functional medicine practice serving women across Texas from offices in Dallas and Austin. Her clinical focus is perimenopause, hormone imbalance, gut health, thyroid and autoimmune conditions, and chronic fatigue.
More about Anna · Schedule a consultation · LinkedIn · Instagram
Medical disclaimer. The information on this page is provided for general education and is not individualized medical advice. At Interlinked Wellness, Anna Evans, MSN, APRN, FNP-C, provides personalized care based on your health history, symptoms, concerns, and goals. An individual consultation allows Anna to evaluate your specific situation and recommend an appropriate approach to care. Reading this page alone does not establish a patient-provider relationship. If you are experiencing a medical emergency, call 911 or your local emergency services.
Join Anna on a virtual wellness journey and unlock your full potential.
